Loading
Life sciences · Journal article
Molecular Cancer · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The dynamic and reversible N 6 -methyladenosine (m 6 A) RNA modification has emerged as a pivotal layer of epitranscriptomic regulation in cancer, governing RNA metabolism and function. Concurrently, deubiquitylating enzymes (DUBs), key components of the post-translational modifications (PTMs) system, orchestrate protein stability and signaling pathways crucial for tumorigenesis. Recent evidence reveals extensive and intricate crosstalk between these two regulatory systems, forming a complex network that can influence cancer progression. This review systematically explores the bidirectional interplay between DUBs and m 6 A modification. On one hand, specific DUBs can deubiquitinate and stabilize core m 6 A “writers” (methyltransferases), “erasers” (demethylases), or “readers” (recognition proteins), thereby influencing RNA metabolism and downstream gene expression. On the other hand, m 6 A modification can regulate the expression of certain DUBs, either by influencing the stability and translation of their mRNAs or by controlling associated regulatory factors. This reciprocal regulation profoundly impacts key oncogenic processes, including cell proliferation, metastasis, metabolic reprogramming, and therapy resistance. By integrating current findings, this review highlights the significance of the DUB-m 6 A axis as a critical regulatory hub in cancer biology. Deciphering this crosstalk not only provides novel insights into tumor mechanisms but also unveils promising therapeutic targets for overcoming drug resistance and developing innovative anti-cancer strategies.